|
|
|
|
| Symbol(s): |
PGNX |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
PGNX has a current Overall Rating of D (Negative). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| PGNX has a current Overall Rating of D (Negative). Appreciation potential (32) is negative; Power Rating (20) is very low. Relative to the S&P 500 Composite, Progenics Pharmaceutical Inc has significant Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. PGNX is of very low investment quality. PGNX's current technical position is very weak. PGNX's Power Rating is 20. However, earnings estimate behavior for PGNX has been slightly favorable recently. ...
| | |
|
|
